2026 Kff

• Researchers have published a new study in Science Translational Medicine detailing how the Epstein-Barr virus triggers immune responses that cause inflammation and nervous system damage in multiple sclerosis patients. • Separately, clinical trials have demonstrated the effectiveness of a treatment that inhibits the PCSK9 protein to significantly lower dangerous LDL cholesterol levels. • This cholesterol treatment can reduce LDL levels to 50 or 60, whereas adults not using medication typically maintain levels above 100.

• The FDA has approved the use of Paxlovid for children aged 12 and older who weigh at least 88 pounds. • AstraZeneca reported that its heart disease drug failed a pivotal trial, marking a significant setback in the company's cardiovascular development goals. • Eli Lilly launched a new website to advocate that obesity is a chronic, complex disease rather than just a risk factor for other medical complications.

• The WHO announced the first patient has entered a randomized platform trial in the Democratic Republic of the Congo to test the monoclonal antibody MBP134 and remdesivir against the Bundibugyo virus. • This clinical trial aims to determine if these antiviral therapies, used alone or in combination, can improve survival rates as Ebola-related cases and deaths continue to rise. • Separately, rising health affordability crises and medical system frustrations are driving increased public and political demand for government intervention regarding drug prices and insurance premiums.